Acute posterior multifocal placoid pigment epitheliopathy: clinical presentation and risk of stroke and transient ischaemic attack

Background/aimsAcute posterior multifocal placoid pigment epitheliopathy is a rare but important disease that can be associated with life-threatening complications due to cerebral vasculitis. The primary objective was to determine the incidence of neurological complications and risk factors for stroke and transient ischaemic attack (TIA) associated with acute posterior multifocal placoid pigment epitheliopathy. Secondary objectives included the clinical presentation, visual outcomes and recurrence rates. MethodsThis was a multicentre retrospective case series including 111 eyes from 60 subjects presenting from January 2009 to June 2020. ResultsMedian age at presentation was 29 years (IQR 24.7-35.1) and 36 subjects (60.0%) were male. 20 subjects (33.3%) reported a viral prodrome. Stroke and TIA were observed in seven subjects (11.7%). Older age was the only significant risk factor for stroke/TIA (p=0.042). Vision loss occurred in seven eyes, with four eyes (3.6%) having final visual acuity 6/15-6/60 and three eyes (2.7%) having visual acuity of 6/60 or worse. Recurrence occurred in 10 subjects (16.7%). ConclusionsThe presence of headache cannot reliably predict those at risk of stroke/TIA. Individuals presenting with acute posterior multifocal pigment epitheliopathy should therefore undergo a clinical neurological review and work-up for cerebral vasculitis as deemed appropriate by the treating ophthalmologist and collaborating neurologist.

Automated summary

Acute posterior multifocal placoid pigment epitheliopathy is a rare but important disease associated with life-threatening complications. The study aimed to determine the incidence of neurological complications and risk factors for stroke and TIA associated with this disease. Results showed that stroke and TIA occurred in 11.7% of subjects, with older age being the only significant risk factor. Vision loss occurred in 7 eyes, and recurrence was observed in 16.7% of patients.